{
    "organizations": [],
    "uuid": "62c994ab196abb8533df111b4c3a736453c5f27e",
    "author": "",
    "url": "https://www.reuters.com/article/gsk-results/currency-weighs-on-glaxosmithkline-q1-sales-and-earnings-idUSASO0003TD",
    "ord_in_thread": 0,
    "title": "Currency weighs on GlaxoSmithKline Q1 sales and earnings",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "LONDON, April 25 (Reuters) - Drugmaker GlaxoSmithKline reported a 2 percent fall in both sales and earnings in the first quarter on Wednesday as a stronger pound offset a promising start for its new shingles vaccine Shingrix.\nGSKâ€™s adjusted earnings per share were 24.6 pence on sales of 7.22 billion pounds ($10.07 billion). Analysts, on average, had forecast 24.25 pence and 7.24 billion pounds, according to Thomson Reuters data. ($1 = 0.7168 pounds) (Reporting by Ben Hirschler, editing by Louise Heavens)\n ",
    "published": "2018-04-25T14:07:00.000+03:00",
    "crawled": "2018-04-25T14:21:51.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "london",
        "april",
        "reuters",
        "drugmaker",
        "glaxosmithkline",
        "reported",
        "percent",
        "fall",
        "sale",
        "earnings",
        "first",
        "quarter",
        "wednesday",
        "stronger",
        "pound",
        "offset",
        "promising",
        "start",
        "new",
        "shingle",
        "vaccine",
        "shingrix",
        "gsk",
        "adjusted",
        "earnings",
        "per",
        "share",
        "penny",
        "sale",
        "billion",
        "pound",
        "billion",
        "analyst",
        "average",
        "forecast",
        "penny",
        "billion",
        "pound",
        "according",
        "thomson",
        "reuters",
        "data",
        "pound",
        "reporting",
        "ben",
        "hirschler",
        "editing",
        "louise",
        "heaven"
    ]
}